Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...
20h
The mammalian immune system is an evolutionary wonder. It's capable of recognizing and destroying cancer cells, and it can ...
Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.
University of Florida researchers have led a multicenter study demonstrating that Automated Imaging Differentiation for ...
Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.
Objective: We aimed to conduct 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET) to investigate the metabolic changes in brain regions associated with cognitive decline in patients ...
Astronaut Sunita Williams and Butch Wilmore have been aboard the International Space Station (ISS) for over nine months due to technical issues with their spacecraft. As they prepare to return, ...
When you think about multiple personalities, what is the first thing that comes to your mind? For many, it is a disturbing picture from a Hollywood film about a deranged and sociopathic murderer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback